HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Abstract

HER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.